Success Story: National Interest Waiver (NIW) Approval for a Researcher Using Real-World Health Data to Improve Medication Access
Client’s Testimonial:
"Thank you so much for helping me get the NIW approval that I've been waiting for so long.”
On July 3rd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Ph.D. Candidate in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Ph.D. Candidate
Country of Origin: Taiwan
State of Residence at the Time of Filing: Minnesota
Approval Notice Date: July 3rd, 2026
Processing Time: 13 months, 6 days (Premium Processing Requested)
Case Summary:
“By linking treatment trends with population health data, his work offers data-driven insights into how healthcare programs are performing and informs strategies to improve equitable access to essential medications.”
This expert comment captured the central value of the client’s research: using real-world health data to understand whether important medications are actually reaching the patients who need them.
The client’s work focused on pharmacoepidemiology and advanced clinical analytics, utilizing large-scale national health databases to evaluate the access patterns, safety, and effectiveness of novel therapeutics in high-risk populations. As an academic researcher, his work examined critical issues such as the clinical outcomes of advanced medications, overall treatment affordability, systemic physiological complications, and healthcare accessibility for underserved demographics.
For this case, North America Immigration Law Group (Chen Immigration Law Associates) did not present the client’s work as general healthcare research. Instead, we emphasized how his studies help answer questions that are highly relevant to U.S. healthcare systems: which patients receive newer therapies, what barriers prevent continued treatment, how real-world outcomes compare across patient groups, and how data can guide more equitable medication use. This framing helped connect the client’s research to public health, cost-effective care, and health equity.
The client’s qualifications supported this argument. He held an M.S. in pharmaceutical sciences, had authored 7 peer-reviewed journal articles, and had received 54 citations. Six of his papers ranked among the most-cited Clinical Medicine articles for their publication years. Additionally, the client's work had received funding from the Ministry of Science and Technology (Republic of China) and the Ministry of Education (Republic of China).
The petition demonstrated how the client’s work had already been actively utilized by independent researchers. His findings informed subsequent studies on barriers to novel therapeutic adoption, systemic disease management, medication affordability, and broader clinical intervention protocols. These examples established that the client’s research was not merely published, but had become a foundational component of ongoing efforts to evaluate treatment accessibility and long-term patient outcomes.
USCIS approved the NIW petition on July 3rd, 2026, after a Premium Processing upgrade on May 13th, 2026. We congratulate the client on this approval and are pleased that NAILG could help present a case showing how real-world evidence research could support better treatment decisions, stronger healthcare programs, and more equitable access to essential medications in the United States.